Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cured from Hodgkin's disease].

Pauline Brice1

  • 1HDJ d'hématologie, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France. pauline.brice@sls.ap-hop-paris.fr

Bulletin Du Cancer
|September 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability and feasibility of post-treatment fertility preservation in women previously treated for hematological diseases.

Haematologica·2026
Same author

Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?

British journal of haematology·2025
Same author

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.

The Lancet. Oncology·2024
Same author

Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome.

Critical reviews in oncology/hematology·2024
Same author

Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.

Haematologica·2024
Same author

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.

Blood advances·2023
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Hodgkin's disease has high cure rates with improved therapies since 1960. Long-term survivors experience manageable side effects and can achieve normal lives and have children.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Context:

  • Hodgkin's disease treatment has evolved significantly since 1960.
  • Current therapeutic strategies achieve high remission rates (80-90%).
  • Understanding long-term outcomes and patient follow-up is crucial.

Purpose:

  • To review Hodgkin's disease remission criteria, focusing on residual masses.
  • To outline long-term patient follow-up protocols.
  • To discuss the spectrum of adverse events and long-term toxicities associated with treatment.

Summary:

  • Remission criteria are detailed, noting residual masses do not impact relapse rates.
  • Follow-up involves regular check-ups for 10 years.
  • Adverse events include acute leukemia (decreasing risk with MOPP chemotherapy reduction) and later solid tumors.

Related Experiment Videos

  • Thyroid diseases are common but often benign.
  • Fertility preservation is good with ABVD chemotherapy, but cardiopulmonary toxicity is a risk with mediastinal radiation.
  • Most survivors achieve normal socioprofessional lives, though fatigue may persist.

    • Impact:

    • Informs clinical practice regarding Hodgkin's disease management and follow-up.
    • Highlights the decreasing risk of acute leukemia with modern chemotherapy.
    • Provides insights into long-term toxicities, aiding in patient counseling and risk mitigation.
    • Supports the understanding of fertility preservation and socioprofessional reintegration for survivors.